TG Therapeutics (NASDAQ:TGTX) Shares Down 5.3%

TG Therapeutics, Inc. (NASDAQ:TGTX – Get Rating)’s stock price was down 5.3% during trading on Friday . The company traded as low as $6.01 and last traded at $6.05. Approximately 13,946 shares traded hands during trading, a decline of 100% from the average daily volume of 2,877,494 shares. The stock had previously closed at $6.39.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on TGTX shares. Bank of America began coverage on TG Therapeutics in a report on Friday, May 20th. They set an “underperform” rating on the stock. StockNews.com upgraded TG Therapeutics to a “sell” rating in a report on Friday, June 17th. Cantor Fitzgerald restated an “overweight” rating on shares of TG Therapeutics in a report on Monday, May 9th. HC Wainwright decreased their price objective on TG Therapeutics from $68.00 to $19.00 and set a “buy” rating on the stock in a report on Monday, April 18th. Finally, B. Riley cut their target price on TG Therapeutics from $23.00 to $17.00 and set a “buy” rating on the stock in a research report on Monday, June 13th. Three analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $21.25.

TG Therapeutics Stock Down 6.3 %

The firm has a 50-day simple moving average of $5.05 and a 200 day simple moving average of $8.03. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.43 and a quick ratio of 4.43. The company has a market capitalization of $865.17 million, a PE ratio of -2.44 and a beta of 2.17.

TG Therapeutics (NASDAQ:TGTX – Get Rating) last announced its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.04. TG Therapeutics had a negative return on equity of 118.49% and a negative net margin of 4,126.45%. The business had revenue of $2.02 million for the quarter, compared to analyst estimates of $1.54 million. On average, research analysts predict that TG Therapeutics, Inc. will post -2.1 EPS for the current fiscal year.

Hedge Funds Weigh In On TG Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. CWM LLC boosted its position in shares of TG Therapeutics by 4,871.4% during the second quarter. CWM LLC now owns 12,180 shares of the biopharmaceutical company’s stock worth $52,000 after buying an additional 11,935 shares during the period. Exane Derivatives bought a new stake in TG Therapeutics during the first quarter worth approximately $54,000. Lazard Asset Management LLC bought a new stake in TG Therapeutics during the first quarter worth approximately $60,000. Baldwin Brothers LLC MA increased its holdings in shares of TG Therapeutics by 250.0% in the first quarter. Baldwin Brothers LLC MA now owns 7,000 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 5,000 shares in the last quarter. Finally, Prospera Financial Services Inc bought a new position in shares of TG Therapeutics in the first quarter valued at $70,000. 70.52% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

(Get Rating)

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.